-
德拉沙星葡甲胺
- names:
Delafloxacin meglumine
- CAS號(hào):
352458-37-8
MDL Number: MFCD26142921 - MF(分子式): C25H29ClF3N5O9 MW(分子量): 635.97
- EINECS: Reaxys Number:
- Pubchem ID:11578213 Brand:BIOFOUNT
| 貨品編碼 | 規(guī)格 | 純度 | 價(jià)格 (¥) | 現(xiàn)價(jià)(¥) | 特價(jià)(¥) | 庫(kù)存描述 | 數(shù)量 | 總計(jì) (¥) |
|---|---|---|---|---|---|---|---|---|
| YZM000170-10mg | 10mg | 99.98% | ¥ 487.50 | ¥ 487.50 | 2-3天 | ¥ 0.00 |
- 大包裝詢價(jià) 提供各種包裝,敬請(qǐng)垂詢
- 收藏商品 商品點(diǎn)評(píng) 加入購(gòu)物車 立即購(gòu)買
| 中文別名 | 德拉沙星葡甲胺(352458-37-8);ABT492葡甲胺; RX-3341葡甲胺; WQ-3034葡甲胺;德拉沙星中間體1;來氟沙星葡甲胺;德拉福沙星葡甲胺;德拉沙星葡甲胺鹽; 1-(6-氨基-3,5-二氟-2-吡啶基)-8-氯-6-氟-1,4-二氫-7-(3-羥基-1-氮雜環(huán)丁基)-4-氧代-3-喹啉羧酸葡甲胺鹽;德拉沙星N-甲基葡萄糖胺鹽;德拉沙星葡甲胺鹽;地拉沙星葡甲胺;德拉沙星葡甲胺;巴克斯德拉 1-(6-氨基-3,5-二氟吡啶-2-基)-8-氯-6-氟-7-(3-羥基氮雜環(huán)丁烷-1-基)-4-氧喹啉-3-羧酸;(2R, 3R,4R,5S)-6-(甲基氨基)己烷-1,2,3,4,5-戊醇; |
| 英文別名 | Delafloxacin meglumine(352458-37-8);ABT492 meglumine; RX-3341 meglumine; WQ-3034 meglumine;Baxdela; D-Glucitol,1-deoxy-1-(methylamino)-,1-(6-amino-3,5-difluoro-2-pyridinyl)-8-chloro-6-fluoro-1,4-dihydro-7-(3-hydroxy-1-azetidinyl)-4-oxo-3-quinolinecarboxylate (salt); 1-Deoxy-1-(methylamino)-D-glucitol 1-(6-amino-3,5-difluoropyridin-2-yl)-8-chloro-6-fluoro-7-(3-hydroxyazetidin-1-yl)-4-oxo-1,4-dihydroquinoline-3-carboxylate (salt); 1-(6-amino-3,5-difluoropyridin-2-yl)-8-chloro-6-fluoro-7-(3-hydroxyazetidin-1-yl)-4-oxoquinoline-3-carboxylic acid,(2R,3R,4R,5S)-6-(methylamino)hexane-1,2,3,4,5-pentol;ABT-492 MegluMine;100850;ABT492meglumine(Delafloxacinmeglumine);Delafloxacinmeglumine(ABT492meglumine;(2R,3R,4R,5S)-2,3,4,5-tetrahydroxy-6-(MethylaMino)hexyl1-(6-aMino-3,5-difluoropyridChemicalbookin-2-yl)-8-chloro-6-fluoro-7-(3-hydroxyazetidin-1-yl)-4-oxo-1,4-dihydroquinoline-3-carboxylate;ABT492MegluMine;ABT492MegluMine;ABT-492MegluMine;Delafloxacin(MegluMine); Baxdela; 1-(6-amino-3,5-difluoropyridin-2-yl)-8-chloro-6-fluoro-7-(3-hydroxyazetidin-1-yl)-4-oxoquinoline-3-carboxylic acid;(2R,3R,4R,5S)-6-(methylamino)hexane-1,2,3,4,5-pentol; |
| CAS號(hào) | 352458-37-8 |
| Inchi | InChI=1S/C18H12ClF3N4O4.C7H17NO5/c19-12-13-7(1-9(20)14(12)25-3-6(27)4-25)15(28)8(18(29)30)5-26(13)17-11(22)2-10(21)16(23)24-17;1-8-2-4(10)6(12)7(13)5(11)3-9/h1-2,5-6,27H,3-4H2,(H2,23,24)(H,29,30);4-13H,2-3H2,1H3/t;4-,5+,6+,7+/m.0/s1 |
| InchiKey | AHJGUEMIZPMAMR-WZTVWXICSA-N |
| 分子式 Formula | C25H29ClF3N5O9 |
| 分子量 Molecular Weight | 635.97 |
| 溶解度Solubility | 生物體外In Vitro:DMSO溶解度≥ 6.4 mg/mL(10.06 mM)*"≥" means soluble可溶, but saturation unknown溶解度未知. |
| 性狀 | 固體粉末,Power |
| 儲(chǔ)藏條件 Storage conditions | -20°C 3 years年 4°C 2 years年 / In solvent溶液中:-80°C 6 months月 -20°C 1 month月 |
德拉沙星葡甲胺(352458-37-8,Delafloxacin,ABT492 meglumine,RX-3341 meglumine,WQ-3034 meglumine)毒理性質(zhì):
Delafloxacin, like other fluoroquinolones, is associated with a low rate (3% to 4%) of serum enzyme elevations during therapy. These abnormalities are generally mild, asymptomatic and transient, resolving even with continuation of therapy. ALT elevations above 5 times the upper limit of normal occur in 1% or less of subjects. Although delafloxacin may not have been clearly linked to cases of clinically apparent liver injury, the other fluoroquinolones, such as ciprofloxacin, levofloxacin and moxifloxacin, rank among the 25 most common causes of drug induced liver injury in many case series. Estimates of the frequency of liver injury from fluoroquinolones have been 1:15,000 to 1:25,000 exposed persons. Delafloxacin has been in clinical use for a short time only, but is likely to have a similar frequency and pattern of liver injury as the other fluoroquinolones. The typical presentation of fluoroquinolone associated liver injury is with a short latency (1 day to 3 weeks) and abrupt onset with nausea, fatigue, abdominal pain and jaundice. The pattern of serum enzyme elevations can be either hepatocellular or cholestatic, cases with the shorter times to onset usually being more hepatocellular. In addition, the onset of illness may occur a few days after the medication is stopped. Many (but not all) cases have prominent allergic manifestations with fever and rash, and the liver injury may occur in the context of a generalized hypersensitivity reaction. Autoantibodies are usually not present. Most reported cases of liver injury from fluoroquinolones have been mild and self-limited, with recovery in 4 to 8 weeks from onset. However, the fatality rate of cases with jaundice has been greater than 10%. In addition, cases with a cholestatic pattern of serum enzymes may run a prolonged course and, in rare instances, have progressed to chronic vanishing bile duct syndrome leading to liver failure. Nevertheless, delafloxacin is a relatively recently introduced antibiotic and has yet to be convincingly linked to instances of acute hepatitis or jaundice. Likelihood score: E* (unproven but suspected cause of clinically apparent liver injury).
德拉沙星葡甲胺(352458-37-8,Delafloxacin,ABT492 meglumine,RX-3341 meglumine,WQ-3034 meglumine)實(shí)驗(yàn)注意事項(xiàng):
1.實(shí)驗(yàn)前需戴好防護(hù)眼鏡,穿戴防護(hù)服和口罩,佩戴手套,避免與皮膚接觸。
2.實(shí)驗(yàn)過程中如遇到有毒或者刺激性物質(zhì)及有害物質(zhì)產(chǎn)生,必要時(shí)實(shí)驗(yàn)操作需要手套箱內(nèi)完成以免對(duì)實(shí)驗(yàn)人員造成傷害
3.實(shí)驗(yàn)后產(chǎn)生的廢棄物需分類存儲(chǔ),并交于專業(yè)生物廢氣物處理公司處理,以免造成環(huán)境污染Experimental considerations:
1. Wear protective glasses, protective clothing and masks, gloves, and avoid contact with the skin during the experiment.
2. The waste generated after the experiment needs to be stored separately, and handed over to a professional biological waste gas treatment company to avoid environmental pollution.
Tags:德拉沙星葡甲胺試劑,德拉沙星葡甲胺雜質(zhì),德拉沙星葡甲胺合成,德拉沙星葡甲胺中間體,德拉沙星葡甲胺密度,德拉沙星葡甲胺溶解度,德拉沙星葡甲胺旋光度,德拉沙星葡甲胺閃點(diǎn),德拉沙星葡甲胺熔點(diǎn),德拉沙星葡甲胺購(gòu)買,
| 產(chǎn)品說明 | 德拉沙星葡甲胺(352458-37-8,Delafloxacin,ABT492 meglumine,RX-3341 meglumine,WQ-3034 meglumine)是廣譜的氟喹諾酮類抗生素 |
| Introduction | Delafloxacin meglumine (ABT492 meglumine; RX341 meglumine; WQ034 meglumine) is a broadpectrum fluoroquinolone antibiotic. Delafloxacin has a broad spectrum of activity that includes drugesistantStaphylococcus aureus,Streptococcus pneumoniae, andKlebsiella pneumonia. |
| Application1 | 德拉沙星葡甲胺可用于細(xì)菌性皮膚和皮膚結(jié)構(gòu)感染的治療(ABSSSI) |
| Application2 | Delafloxacin meglumine (ABT492 meglumine; RX-3341 meglumine; WQ-3034 meglumine) 是一種廣譜氟喹諾酮類抗生素。Delafloxacin 具有廣泛的活性,對(duì)耐藥性的金黃色葡萄球菌,肺炎鏈球菌和肺炎克雷伯菌都有效。 |
| Application3 |
1、德拉沙星葡甲胺是氟喹諾酮類抗生素。IC50值:耐左氧氟沙星的肺炎鏈球菌菌株的MIC范圍為0.0078至0.125 micro g / ml;目標(biāo):抗菌;ABT-492對(duì)喹諾酮敏感和耐藥的革蘭氏陽性生物更有效,對(duì)環(huán)丙沙星家族腸桿菌科某些成員的活性與環(huán)丙沙星相似,對(duì)喹諾酮敏感,非發(fā)酵性,革蘭氏陰性生物的活性相當(dāng)。體外:ABT-492對(duì)用MICs測(cè)試的所有326種需氧和厭氧竇穿刺竇分離物均表現(xiàn)出優(yōu)異的體外活性(以微克/毫升計(jì)),其中90%的分離物被抑制如下:流感嗜血桿菌,0.001;卡他莫拉氏菌0.008; 和肺炎鏈球菌,0.015 。
2、德拉沙星葡甲胺是一種氟喹諾酮,可用于治療成年患者的急性細(xì)菌性皮膚和皮膚結(jié)構(gòu)感染(ABSSSI)。研究表明,德拉沙星葡甲胺對(duì)肝臟和腎臟具有優(yōu)異的耐受性和低毒性。
| 警示圖 | |
| 危險(xiǎn)性 | warning |
| 危險(xiǎn)性警示 | Not available |
| 安全聲明 | H303吞入可能有害+H313皮膚接觸可能有害+H2413吸入可能對(duì)身體有害 |
| 安全防護(hù) | P264處理后徹底清洗+P280戴防護(hù)手套/穿防護(hù)服/戴防護(hù)眼罩/戴防護(hù)面具+P305如果進(jìn)入眼睛+P351用水小心沖洗幾分鐘+P338取出隱形眼鏡(如果有)并且易于操作,繼續(xù)沖洗+P337如果眼睛刺激持續(xù)+P2393獲得醫(yī)療建議/護(hù)理 |
| 備注 | 實(shí)驗(yàn)過程中防止吸入、食入,做好安全防護(hù) |
| Lepak AJ, et al. In Vivo Pharmacodynamic Target Assessment of Delafloxacin against Staphylococcus aureus, Streptococcus pneumoniae, and Klebsiella pneumoniae in a Murine Lung Infection Model. Antimicr |
1、Delafloxacin meglumine for the treatment of acute bacterial skin and skin structure infections (ABSSSI)
G Kaul 1, E Kapoor 1, A Dasgupta 1, S Chopra
Abstract Delafloxacin meglumine (Baxdela, WQ-3034, ABT-492, RX-3341; Melinta Therapeutics) was approved by the U.S. Food and Drug Administration (FDA) in June 2017 for the treatment of acute bacterial skin and skin structure infections on the basis of data from two phase III trials. Delafloxacin is a broad-spectrum anionic fluoroquinolone and its distinct chemical structure increases its potency in acidic environments. It is known to inhibit DNA replication and repair by targeting DNA gyrase and topoisomerase IV. Delafloxacin is administered via both oral and parenteral routes. It has potent activity against methicillin-resistant Staphylococcus aureus and Streptococci, and is also effective against Enterobacteriaceae and Pseudomonas aeruginosa. Delafloxacin is currently in phase III evaluation for treatment of community-acquired pneumonia and was classified as a qualified infectious disease product by the U.S. FDA in its approval.
2、In Vivo Pharmacodynamic Target Assessment of Delafloxacin against Staphylococcus aureus, Streptococcus pneumoniae, and Klebsiella pneumoniae in a Murine Lung Infection Model
Alexander J Lepak 1, David R Andes 2
Abstract Delafloxacin is a broad-spectrum anionic fluoroquinolone under development for the treatment of bacterial pneumonia. The goal of the study was to determine the pharmacokinetic/pharmacodynamic (PK/PD) targets in the murine lung infection model for Staphylococcus aureus, Streptococcus pneumoniae, and Klebsiella pneumoniae Four isolates of each species were utilized for in vivo studies: for S. aureus, one methicillin-susceptible and three methicillin-resistant isolates; S. pneumoniae, two penicillin-susceptible and two penicillin-resistant isolates; K. pneumoniae, one wild-type and three extended-spectrum beta-lactamase-producing isolates. MICs were determined using CLSI methods. A neutropenic murine lung infection model was utilized for all treatment studies, and drug dosing was by the subcutaneous route. Single-dose plasma pharmacokinetics was determined in the mouse model after administration of 2.5, 10, 40, and 160 mg/kg. For in vivo studies, 4-fold-increasing doses of delafloxacin (range, 0.03 to 160 mg/kg) were administered every 6 h (q6h) to infected mice. Treatment outcome was measured by determining organism burden in the lung (CFU counts) at the end of each experiment (24 h). The Hill equation for maximum effect (Emax) was used to model the dose-response data. The magnitude of the PK/PD index, the area under the concentration-time curve over 24 h in the steady state divided by the MIC (AUC/MIC), associated with net stasis and 1-log kill endpoints was determined in the lung model for all isolates. MICs ranged from 0.004 to 1 mg/liter. Single-dose PK parameter ranges include the following: for maximum concentration of drug in serum (Cmax), 2 to 70.7 mg/liter; AUC from 0 h to infinity (AUC0-∞), 2.8 to 152 mg · h/liter; half-life (t1/2), 0.7 to 1 h. At the start of therapy mice had 6.3 ± 0.09 log10 CFU/lung. In control mice the organism burden increased 2.1 ± 0.44 log10 CFU/lung over the study period. There was a relatively steep dose-response relationship observed with escalating doses of delafloxacin. Maximal organism reductions ranged from 2 log10 to more than 4 log10 The median free-drug AUC/MIC magnitude associated with net stasis for each species group was 1.45, 0.56, and 40.3 for S. aureus, S. pneumoniae, and K. pneumoniae, respectively. AUC/MIC targets for the 1-log kill endpoint were 2- to 5-fold higher. Delafloxacin demonstrated in vitro and in vivo potency against a diverse group of pathogens, including those with phenotypic drug resistance to other classes. These results have potential relevance for clinical dose selection and evaluation of susceptibility breakpoints for delafloxacin for the treatment of lower respiratory tract infections involving these pathogens.
- 相關(guān)產(chǎn)品
-
< >
- 推薦產(chǎn)品
-
< >
- 最新產(chǎn)品
-
< >
新聞
胞爬片免疫組化染色.png)
怎么做細(xì)胞爬片免疫組化染色實(shí)驗(yàn)
細(xì)胞爬片免疫組化染色,是通過細(xì)胞爬片是讓玻片浸在細(xì)胞培養(yǎng)基內(nèi),細(xì)胞在玻片上生長(zhǎng),主要用于組織學(xué),免疫組織化學(xué)...
2020/7/20 22:04:33

提取病毒RNA的實(shí)驗(yàn)方法
提取病毒RNA方法分別有:異硫氰酸胍的提取病毒RNA方法、TRIzol LS提取法、Trizol法提取法等等...
2020/7/22 20:29:26

9月開學(xué)季——助研新學(xué)期 范德送好禮
2025/8/28 15:30:55

Waxfilm 實(shí)驗(yàn)室封口膜:技術(shù)與國(guó)際市場(chǎng)的雙重突破
在實(shí)驗(yàn)室耗材領(lǐng)域,封口膜是保障實(shí)驗(yàn)準(zhǔn)確性與穩(wěn)定性的關(guān)鍵產(chǎn)品之一。近年來,Waxfilm?實(shí)驗(yàn)室封口膜憑借其卓...
2025/5/13 13:03:40

Waxfilm實(shí)驗(yàn)室封口膜的5大突破
Waxfilm實(shí)驗(yàn)室封口膜作為生物功能膜領(lǐng)域的國(guó)產(chǎn)技術(shù)突破和品牌突破,是生物領(lǐng)域中國(guó)技術(shù)發(fā)展的縮影。
2025/5/6 17:02:07

各種微流控芯片鍵合方法的優(yōu)缺點(diǎn)
微流控芯片鍵合:目前主要有激光焊接、熱壓鍵合、膠鍵合、超音波焊接,每種方法都有各自的優(yōu)缺點(diǎn)。本文主要介紹聚酯...
2023/7/28 10:43:09

新一代微流控鍵合解決方案
微流控鍵合解決方案:微流控芯片制造的一個(gè)重要環(huán)節(jié),也是最容易被忽視的--芯片鍵合。其中一個(gè)重要因素是:微流控...
2023/7/27 12:44:28
驗(yàn)動(dòng)物圖.png)
熒光素鉀鹽使用說明
D-熒光素鉀鹽(K+)設(shè)計(jì)用于體外和體內(nèi)生物發(fā)光測(cè)定。D-熒光素的質(zhì)量和純度對(duì)于獲得良好和可重復(fù)的結(jié)果至關(guān)重...
2023/7/20 11:05:11

如何選BSA(牛血清白蛋白)
如何選BSA(牛血清白蛋白):牛血清白蛋白(BSA)有多種形式,如何選擇適合自己的牛血清白蛋白(BSA)是一...
2023/2/14 13:09:18

牛血清白蛋白(BSA)常見問題
牛血清白蛋白(BSA)常見問題:牛血清白蛋白(BSA)在實(shí)驗(yàn)室中是通用的,可用于蛋白質(zhì)印跡、細(xì)胞組織培養(yǎng)、P...
2022/10/19 9:39:51



購(gòu)物車 


